Scientists uncover protein clues to sepsis danger
NCT ID NCT06541600
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This study looked at 567 intensive care patients to find early warning signs of severe sepsis. Researchers measured proteins in the blood, especially one called MMP-3, to see if they could predict organ damage or death. The goal was to better understand why some people get worse, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
567 people
The number who actually took part.
- Started
-
Jun 2017
- Finished
-
Oct 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Critical ill patients without sepsis; Patients with sepsis and patients diagnosed with septic cardiomyopathy.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age \>= 18 years old. 2. Admitted to the Intensive Care Unit (ICU) with an anticipated length of stay exceeding 24 hours. 3. Patient or legally authorized representative provides written informed consent prior to enrollment. 4. Categorized into one of the following three mutually exclusive cohorts within 24 hours of ICU admission: * Cohort 1 (Non-sepsis Controls): Admitted for definitive non-infectious etiologies (e.g., severe trauma, major non-cardiac surgery) with no clinical or microbiological evidence of infection throughout the ICU stay. * Cohort 2 (Sepsis without SIC): Diagnosed with sepsis according to the Sepsis-3 criteria (acute change in SOFA score \>= 2 points driven by infection), but with normal cardiac troponin levels and preserved cardiac function. * Cohort 3 (Sepsis-Induced Cardiomyopathy, SIC): Diagnosed with sepsis according to the Sepsis-3 criteria, accompanied by new-onset myocardial injury (elevated cardiac troponin above the upper limit of normal) and/or echocardiographic evidence of myocardial dysfunction directly attributable to sepsis. Exclusion Criteria: 1. Pre-existing severe chronic cardiac conditions, including history of cardiac surgery, severe pre-existing heart failure (NYHA Class III or IV), persistent severe arrhythmias, or known primary cardiomyopathy (e.g., hypertrophic or dilated cardiomyopathy). 2. Acute non-infectious cardiovascular or cerebrovascular events prior to or upon ICU admission, such as acute myocardial infarction (Type 1), acute ischemic/hemorrhagic stroke, or cardiac arrest. 3. Severe end-stage comorbidities, including end-stage renal disease (ESRD) requiring chronic maintenance dialysis prior to this illness, Child-Pugh Class C hepatic cirrhosis, or advanced malignant tumors with a life expectancy \< 3 months. 4. History of paraquat poisoning or other toxic ingestions known to directly cause profound myocardial or pulmonary toxicity. 5. Pregnant or breastfeeding women. 6. Indeterminate or ambiguous infectious status (e.g., cases treated with empiric antibiotics for suspected infection but where infection could neither be confirmed nor ruled out), excluded to prevent misclassification bias. 7. Intellectual, psychological, or neurological disorders that preclude necessary clinical examinations or compliance with study procedures.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sepsis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two blood markers catch sepsis before it turns deadly?
- Two cheap blood ratios put to the test as sepsis death predictors
- Can a computer model speed up sepsis blood tests?
- Stem cells put to the test against Sepsis's immune chaos
- Can the immune system reveal who will suffer kidney injury after sepsis?
- A routine calcium reading could reveal how sick a sepsis patient really is